Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 4 Multicenter, Multinational, Prospective, Randomized, Placebo-Controlled, Double-Blinded Parallel Group Study to Assess Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D) in Patients Who Report Inadequate Control of IBS-D Symptoms With Prior Loperamide Use (RELIEF)

X
Trial Profile

A Phase 4 Multicenter, Multinational, Prospective, Randomized, Placebo-Controlled, Double-Blinded Parallel Group Study to Assess Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D) in Patients Who Report Inadequate Control of IBS-D Symptoms With Prior Loperamide Use (RELIEF)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Dec 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eluxadoline (Primary)
  • Indications Irritable bowel syndrome
  • Focus Therapeutic Use
  • Acronyms RELIEF
  • Sponsors Allergan
  • Most Recent Events

    • 13 Oct 2020 Results of aggregated pooled analysis from two phase III studies: NCT01553591 and NCT01553747 and one phase IV study: RELIEF presented at the 28th United European Gastroenterology Week
    • 24 Oct 2018 Results presented at the 26th United European Gastroenterology Week
    • 10 Oct 2018 Primary endpoint has been met. (Percentage of Primary Composite Responders) as per results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2018

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top